<DOC>
	<DOC>NCT01777048</DOC>
	<brief_summary>The overarching aim of the proposed study is to assess whether omega-3 fatty acids supplementation can augment the effects of methylphenidate in children with ADHD. The investigators hypothesized that omega-3 fatty acids supplementation will be associated with improved ADHD symptoms.</brief_summary>
	<brief_title>Omega-3 Fatty Acids Supplementation in ADHD</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<criteria>Participants between ages 6 and 12 years who: 1. have been clinically diagnosed with ADHD by a physician 2. meet the criteria of ADHDInattention, ADHDHyperactivityImpulsivity, or ADHDCombined type as determined by the SNAPIV (Swanson, 1992) 3. are willing to participate in a randomized, doubleblind, placebocontrolled trial, complete with written, informed parental consent, 4. are on stable dosage of methylphenidate treatment before the start of the study 5. are able to speak English or German 1. Participants who are younger than 6 years old or older than 12 years old 2. Those who have not been clinically diagnosed with ADHD by a physician 3. Those who did not meet the criteria of ADHDInattention, ADHDHyperactivityImpulsivity, or ADHDCombined type as determined by the SNAPIV (Swanson, 1992) 4. Those without written parental consent 5. Those with brain pathology such as serious head injury, epilepsy, and intellectual disability (IQ &lt; 70) 6. Those with titrated dosage of methylphenidate before the start of the study 7. Those on neurofeedback training, and/or psychosocial intervention addressing attention problems 8. Those with known hypersensitivity to the IMP under investigation 9. Those who are unable to read and understand the parent/participant information 10. Those receiving medications other than methylphenidate</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>